4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT's 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in November 2025. The employee received non-qualified stock options to purchase 53,060 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $12.88 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the f

Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy and in combination with standard of care therapies in mutant or wild-type PIK3CA breast cancer modelsBBOT will also present a trial in progress poster on BREAKER-101, a Phase 1 clinical trial evaluating BBO-10203 in patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer with initial Phase 1 data expected in the first half of 2026 SOUTH SAN FRANCISCO, Calif., Dec. 10, 2

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in December. Details of the company's participation are as follows: Piper Sandler 37th Annual Healthcare ConferencePresentation: Tuesday, December 2, at 2:00 p.m. ET 8th Annual Evercore Healthcare ConferencePresentation: Wednesday, December 3, at 9:35 a.m. ET Live webcasts of the presentations will be accessible on the "Events" page of the BBOT website at https://investors.bbotx.co

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in a presentation at the Jefferies Global Healthcare Conference on Monday, November 17, at 2:30 p.m. GMT.   A live webcast of the presentation will be accessible on the "Events" page of the BBOT website at https://investors.bbotx.com/news-events/events. A replay of the webcast will be available for at least 90 days following the event. About BBOTBBOT is a clinical-stage biopharmaceutical company advancing a nex

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced two poster presentations featuring BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, at the San Antonio Breast Cancer Symposium (SABCS) being held December 9-12, 2025, in San Antonio, Texas. The abstracts released today can be found on the SABCS website here. Late Breaking Pre-clinical Poster Details: Title: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination wit

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with BBOT's KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well-tolerated dose levels in a panel of KRAS-mutant modelsThe combination of a KRAS inhibitor with a PI3Kα pathway inhibitor may maximize the response rate and reduce the development of adaptive resistance mechanisms due to full inhibition of both MAPK and PI3Kα signalingBBOT-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR

Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) modelsBBO-11818's selectivity for KRAS demonstrated by its >1000-fold lower potency against NRAS, HRAS, and BRAF-mutant cell linesEfficacy of the combination with BBOT's RAS:PI3K⍺ breaker, BBO-10203, is driven by a robust decrease in tumor cell proliferation and increase in apoptosis; combination benefit also observed with cetuximab and anti-PD-1 treatment BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in patients with KRAS mutant pancreatic, non-small cell lung, and colorectal

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 22-26, 2025, in Boston, Massachusetts. The abstracts released today can be found on the AACR website here. Details on the abstracts are as follows: Title: BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical modelsSessio

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in September. Details of the company's participation are as follows: Cantor Global Healthcare Conference Fireside Chat: Thursday, September 4 at 8:35 a.m. ET as well as hosting investor meetings in New York Morgan Stanley Global Healthcare Conference Fireside Chat: Monday, September 8 at 7:45 a.m. ET as well as hosting investor meetings in New York Links for live webcasts and replays, if

SCHEDULE 13G/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

SCHEDULE 13G/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)

10-Q - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

S-8 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

EFFECT - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar